Answers are grounded in this paper and cite their sources.
LAG-3 (CD223) is a cell surface protein that is present on activated T cells, NK cells, B cells, and plasmacytoid dendritic cells. It plays a crucial but not yet fully understood role in the activity of these immune cells. LAG-3 primarily interacts with Class II MHC molecules, and this interaction is believed to influence dendritic cell function. Recent research has highlighted LAG-3's involvement in the exhaustion of CD8+ T cells, a state that impairs their effectiveness against tumors. Therapeutic approaches that block the interaction between LAG-3 and Class II MHC, such as the use of a LAG-3 Ig fusion protein, are currently being explored in clinical trials for cancer treatment. This review will provide an overview of the structural and functional aspects of LAG-3, followed by a discussion of preclinical and clinical findings relevant to its role in cancer immunotherapy
No takes yet. Share an insight, caveat, or question.
Tathe et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: